Dr. Cutie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-726-2797Fax+1 617-726-6131- Is this information wrong?
Education & Training
Massachusetts General Hospital/Harvard Medical SchoolResidency, Urology, 2005 - 2008- Massachusetts General HospitalResidency, Surgery, 2003 - 2005
Yale School of MedicineClass of 2003
Certifications & Licensure
MA State Medical License 2008 - 2023- American Board of Urology Urology
Clinical Trials
- Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder Start of enrollment: 2017 Apr 04
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Start of enrollment: 2019 Jan 02
Publications & Presentations
PubMed
- The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-ris...F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, Sumeet Bhanvadia, Kirk A Keegan, Shalaka Hampras, Hussein Sweiti, John C Maffeo, Shu Jin, A...> ;European Urology Open Science. 2024 Apr 1
- Reply by Authors.Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J Dickstein, Félix Guerrero-Ramos, Kristen R Scarpato, Jason M Hafron, Edward M Messing...> ;The Journal of Urology. 2023 May 1
- 1 citationsSafety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phas...Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J Dickstein, Félix Guerrero-Ramos, Kristen R Scarpato, Jason M Hafron, Edward M Messing...> ;The Journal of Urology. 2023 May 1
- Join now to see all
Other
- Overview of vasectomyCutie CJ, Ongaro TJ
http://www.uptodate.com/contents/overview-of-vasectomy
UpToDate, Wolters Kluwer Health - 2009-09-23
Press Mentions
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder CancerApril 30th, 2023
TARIS Initiates Clinical Trial of TAR-200 in Combination with Opdivo® (Nivolumab) for Patients with Muscle-Invasive Bladder CancerJuly 11th, 2019
Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent TherapyMarch 14th, 2018- Join now to see all
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
